Payment overview · 2025
General Payments
$83.57
4 reported records · 4 companies
Healthcare provider profile · identity verified
Michael Carl Madden, MD
Allopathic & Osteopathic Physicians|Family Medicine · MOBILE, AL · NPI 1861444689
Verified facts
What the public records show
CMS Open Payments records show Michael Carl Madden, MD received $83.57 in general payments during 2025 across 4 reported records.
Ethicon US, LLC accounted for 34.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Paxlovid, Rexulti.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 97 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Ethicon US, LLC | Unresolved — no canonical attribution shown | $28.87 | 34.5% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $22.61 | 27.1% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $18.26 | 21.9% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $13.83 | 16.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $83.57 | 4 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| DERMABOND Normalized: dermabond |
Device | Ethicon US, LLC | $28.87 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $22.61 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $22.61 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $18.26 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $13.83 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 14 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
97 | 19 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
14 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 1039 | 113 |
| Gabapentin | Gabapentin | 614 | 126 |
| Meloxicam | Meloxicam | 578 | 136 |
| Atorvastatin Calcium | Atorvastatin Calcium | 575 | 161 |
| Alprazolam | Alprazolam | 571 | 65 |
| Hydrochlorothiazide | Hydrochlorothiazide | 485 | 120 |
| Lisinopril | Lisinopril | 435 | 111 |
| Amlodipine Besylate | Amlodipine Besylate | 353 | 95 |
| Tramadol Hcl | Tramadol Hcl | 347 | 82 |
| Omeprazole | Omeprazole | 326 | 92 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 316 | 90 |
| Potassium Chloride | Potassium Chloride | 310 | 74 |
| Tizanidine Hcl | Tizanidine Hcl | 298 | 53 |
| Levothyroxine Sodium | Levothyroxine Sodium | 266 | 61 |
| Trazodone Hcl | Trazodone Hcl | 256 | 70 |
| Metformin Hcl | Metformin Hcl | 240 | 69 |
| Losartan Potassium | Losartan Potassium | 238 | 59 |
| Pantoprazole Sodium | Pantoprazole Sodium | 216 | 60 |
| Metoprolol Succinate | Metoprolol Succinate | 211 | 57 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 194 | 53 |
| Furosemide | Furosemide | 191 | 51 |
| Promethazine Hcl | Promethazine Hcl | 170 | 44 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 166 | 62 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 154 | 19 |
| Ondansetron Hcl | Ondansetron Hcl | 149 | 49 |
| Pravastatin Sodium | Pravastatin Sodium | 140 | 36 |
| Pioglitazone Hcl | Pioglitazone Hcl | 138 | 32 |
| Sertraline Hcl | Sertraline Hcl | 131 | 30 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 128 | 29 |
| Meclizine Hcl | Meclizine Hcl | 124 | 41 |
| Cefdinir | Cefdinir | 122 | 80 |
| Januvia | Sitagliptin Phosphate | 122 | 25 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 122 | 42 |
| Zolpidem Tartrate | Zolpidem Tartrate | 119 | 14 |
| Celecoxib | Celecoxib | 115 | 26 |
| Allopurinol | Allopurinol | 114 | 29 |
| Glipizide Er | Glipizide | 114 | 26 |
| Ibuprofen | Ibuprofen | 114 | 28 |
| Indapamide | Indapamide | 110 | 29 |
| Fluoxetine Hcl | Fluoxetine Hcl | 109 | 21 |
| Baclofen | Baclofen | 108 | 23 |
| Escitalopram Oxalate | Escitalopram Oxalate | 107 | 20 |
| Azithromycin | Azithromycin | 104 | 55 |
| Pregabalin | Pregabalin | 102 | 14 |
| Clonazepam | Clonazepam | 101 | 15 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 98 | 63 |
| Eliquis | Apixaban | 97 | 19 |
| Fluticasone Propionate | Fluticasone Propionate | 94 | 39 |
| Hydralazine Hcl | Hydralazine Hcl | 94 | 24 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 92 | 36 |
| Clopidogrel | Clopidogrel Bisulfate | 92 | 29 |
| Dicyclomine Hcl | Dicyclomine Hcl | 92 | 29 |
| Carvedilol | Carvedilol | 91 | 31 |
| Ezetimibe | Ezetimibe | 91 | 33 |
| Diclofenac Sodium | Diclofenac Sodium | 89 | 20 |
| Famotidine | Famotidine | 89 | 29 |
| Tamsulosin Hcl | Tamsulosin Hcl | 89 | 31 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 87 | 38 |
| Doxycycline Hyclate | Doxycycline Hyclate | 81 | 59 |
| Fluconazole | Fluconazole | 77 | 27 |
| Diazepam | Diazepam | 75 | suppressed |
| Ozempic | Semaglutide | 75 | 17 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 72 | 19 |
| Citalopram Hbr | Citalopram Hydrobromide | 70 | 16 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 70 | 14 |
| Ondansetron Odt | Ondansetron | 68 | 12 |
| Donepezil Hcl | Donepezil Hcl | 64 | 17 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 64 | 16 |
| Duloxetine Hcl | Duloxetine Hcl | 63 | 16 |
| Montelukast Sodium | Montelukast Sodium | 63 | 15 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 62 | 19 |
| Simvastatin | Simvastatin | 62 | 20 |
| Metoprolol Tartrate | Metoprolol Tartrate | 59 | 18 |
| Clindamycin Hcl | Clindamycin Hcl | 58 | 42 |
| Methocarbamol | Methocarbamol | 55 | 14 |
| Nitroglycerin | Nitroglycerin | 54 | 24 |
| Amoxicillin | Amoxicillin | 53 | 41 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 49 | 15 |
| Lorazepam | Lorazepam | 49 | suppressed |
| Linzess | Linaclotide | 46 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 45 | 16 |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 45 | 12 |
| Alendronate Sodium | Alendronate Sodium | 44 | 17 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 43 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 42 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 39 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 39 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 38 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 38 | suppressed |
| Xarelto | Rivaroxaban | 38 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 37 | suppressed |
| Jardiance | Empagliflozin | 37 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 37 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 36 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 36 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 35 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 35 | suppressed |
| Estradiol | Estradiol | 34 | suppressed |
| Naproxen | Naproxen | 34 | suppressed |
| Sucralfate | Sucralfate | 32 | suppressed |
| Atenolol | Atenolol | 31 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 31 | 12 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 30 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 30 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 29 | suppressed |
| Mounjaro | Tirzepatide | 28 | suppressed |
| Spironolactone | Spironolactone | 28 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 27 | suppressed |
| Memantine Hcl | Memantine Hcl | 27 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 27 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 27 | 13 |
| Lovastatin | Lovastatin | 26 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 26 | suppressed |
| Aripiprazole | Aripiprazole | 25 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 24 | suppressed |
| Temazepam | Temazepam | 24 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 23 | suppressed |
| Valsartan | Valsartan | 23 | suppressed |
| Acyclovir | Acyclovir | 22 | 11 |
| Finasteride | Finasteride | 22 | suppressed |
| Indomethacin | Indomethacin | 22 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 22 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 22 | suppressed |
| Topiramate | Topiramate | 22 | suppressed |
| Glipizide | Glipizide | 21 | suppressed |
| Testosterone | Testosterone | 21 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 20 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 19 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 19 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 19 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 18 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 18 | suppressed |
| Invega Sustenna | Paliperidone Palmitate | 18 | suppressed |
| Nystatin | Nystatin | 18 | suppressed |
| Levetiracetam | Levetiracetam | 16 | suppressed |
| Torsemide | Torsemide | 16 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 15 | suppressed |
| Bupropion Xl | Bupropion Hcl | 15 | suppressed |
| Entresto | Sacubitril/Valsartan | 15 | suppressed |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 15 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 15 | suppressed |
| Mirtazapine | Mirtazapine | 15 | suppressed |
| Rexulti | Brexpiprazole | 15 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 14 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 14 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 14 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 14 | suppressed |
| Lansoprazole | Lansoprazole | 14 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 14 | 14 |
| Amiodarone Hcl | Amiodarone Hcl | 13 | suppressed |
| Cartia Xt | Diltiazem Hcl | 13 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 13 | suppressed |
| Ibu | Ibuprofen | 13 | suppressed |
| Lamotrigine | Lamotrigine | 13 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 13 | suppressed |
| Ramipril | Ramipril | 13 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 12 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 12 | suppressed |
| Hydrocortisone | Hydrocortisone | 12 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 12 | suppressed |
| Levofloxacin | Levofloxacin | 12 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 12 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 12 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 12 | suppressed |
| Suboxone | Buprenorphine Hcl/Naloxone Hcl | 12 | suppressed |
| Ubrelvy | Ubrogepant | 12 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 11 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 11 | suppressed |
| Methotrexate | Methotrexate Sodium | 11 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 11 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $83.57 · 4 records | Ethicon US, LLC | CAPLYTA, DERMABOND, NURTEC ODT, PAXLOVID, REXULTI | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Paxlovid play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Otsuka America Pharmaceutical, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error